GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Camurus AB (OTCPK:CAMRF) » Definitions » EV-to-EBIT

Camurus AB (Camurus AB) EV-to-EBIT : 52.52 (As of May. 15, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Camurus AB EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Camurus AB's Enterprise Value is $2,779.4 Mil. Camurus AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $52.9 Mil. Therefore, Camurus AB's EV-to-EBIT for today is 52.52.

The historical rank and industry rank for Camurus AB's EV-to-EBIT or its related term are showing as below:

CAMRF' s EV-to-EBIT Range Over the Past 10 Years
Min: -1129.34   Med: -15.66   Max: 423.87
Current: 52.61

During the past 13 years, the highest EV-to-EBIT of Camurus AB was 423.87. The lowest was -1129.34. And the median was -15.66.

CAMRF's EV-to-EBIT is ranked worse than
85.48% of 427 companies
in the Biotechnology industry
Industry Median: 10.05 vs CAMRF: 52.61

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Camurus AB's Enterprise Value for the quarter that ended in Mar. 2024 was $2,443.1 Mil. Camurus AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $52.9 Mil. Camurus AB's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 2.17%.


Camurus AB EV-to-EBIT Historical Data

The historical data trend for Camurus AB's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Camurus AB EV-to-EBIT Chart

Camurus AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -11.20 -47.18 -71.40 181.07 52.24

Camurus AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 79.07 28.47 27.39 52.24 47.31

Competitive Comparison of Camurus AB's EV-to-EBIT

For the Biotechnology subindustry, Camurus AB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Camurus AB's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Camurus AB's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Camurus AB's EV-to-EBIT falls into.



Camurus AB EV-to-EBIT Calculation

Camurus AB's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=2779.413/52.917
=52.52

Camurus AB's current Enterprise Value is $2,779.4 Mil.
Camurus AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $52.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Camurus AB  (OTCPK:CAMRF) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Camurus AB's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 ) =EBIT / Enterprise Value (Q: Mar. 2024 )
=52.917/2443.11314
=2.17 %

Camurus AB's Enterprise Value for the quarter that ended in Mar. 2024 was $2,443.1 Mil.
Camurus AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $52.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Camurus AB EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Camurus AB's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Camurus AB (Camurus AB) Business Description

Traded in Other Exchanges
Address
Ideon Science Park, Lund, SWE, SE-223 70
Camurus AB is a research and development-focused pharmaceutical company. It develops pharmaceuticals for the treatment of serious and chronic diseases such as opioid addiction, pain, cancer, and endocrine diseases. The company's product pipeline includes CAM2038, CAM2029, CAM2032, and others. The company's geographical revenue includes Europe (of which Sweden), the United States of America, Australia, and Other geographical areas.